The Shuganhuazheng Formula in Triple-Negative Breast Cancer: A Study Based on Network Pharmacology and In Vivo Experiments

Overview

Journal Evid Based Complement Alternat Med

Specialty Rehabilitation Medicine

Date 2021 Jan 8

PMID 33414839

Citations 2

Authors

Bo Wang

Rui Fei

Yan Yang

Niancai Jing

Yi Lu

Hongyu Xiao

Jili Yang

Yue Zhang

Affiliations

Soon will be listed here.

Abstract

Breast cancer is the most common cancer in women. Among breast cancer subtypes, triple-negative breast cancer (TNBC) has the highest degree of malignancy and the worst prognosis. The Shuganhuazheng formula (SGHZF) is a traditional Chinese herbal formula for the treatment of TNBC, but the mechanism of SGHZF in the treatment of TNBC remains unclear. In this study, the therapeutic effect and mechanism of SGHZF against TNBC were preliminarily determined based on in vivo experimental verification and network pharmacology. In terms of therapeutic effects, the antitumour effect was verified by measuring and calculating tumour volume, and the expression of proto-oncogene c-Myc was verified by PCR. In terms of the mechanism, potential therapeutic targets were identified by overlapping the SGHZF-related and TNBC-related targets. After comprehensively analysing the results of the protein-protein interaction (PPI), gene ontology (GO) function, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses, Akt and HIF-1 were selected for verification by using immunohistochemical and Western blot analyses. The results of the study indicated that SGHZF can inhibit breast tumour growth in mice and that the mechanism may be related to the inhibition of Akt and HIF-1 expression.

Citing Articles

Modulatory Effects of XIAOPI Formula on CXCL1 and Selected Outcomes in Triple-Negative Breast Cancer: A Randomized Controlled Clinical Trial.

Guo L, Hong S, Wang X, Wang S, Wang N, Wei X Breast Cancer (Dove Med Press). 2024; 16:289-303.

PMID: 38835647 PMC: 11149640. DOI: 10.2147/BCTT.S462296.

Effects of Chinese Herbal Formula on Immune Function and Nutritional Status of Breast Cancer Patients.

Liu M Comput Math Methods Med. 2022; 2022:5900024.

PMID: 35872927 PMC: 9303106. DOI: 10.1155/2022/5900024.

References

Schlicher L, Wissler M, Preiss F, Brauns-Schubert P, Jakob C, Dumit V . SPATA2 promotes CYLD activity and regulates TNF-induced NF-κB signaling and cell death. EMBO Rep. 2016; 17(10):1485-1497. PMC: 5048381. DOI: 10.15252/embr.201642592. View

Fishilevich S, Zimmerman S, Kohn A, Iny Stein T, Olender T, Kolker E . Genic insights from integrated human proteomics in GeneCards. Database (Oxford). 2016; 2016. PMC: 4820835. DOI: 10.1093/database/baw030. View

Li X, Yang J, Peng L, Sahin A, Huo L, Ward K . Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat. 2016; 161(2):279-287. DOI: 10.1007/s10549-016-4059-6. View

Wang J, Qi H, Zhang X, Si W, Xu F, Hou T . Saikosaponin D from Radix Bupleuri suppresses triple-negative breast cancer cell growth by targeting β-catenin signaling. Biomed Pharmacother. 2018; 108:724-733. DOI: 10.1016/j.biopha.2018.09.038. View

Shannon A, Bouchier-Hayes D, Condron C, Toomey D . Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev. 2003; 29(4):297-307. DOI: 10.1016/s0305-7372(03)00003-3. View

Muz B, de la Puente P, Azab F, Azab A . The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl). 2016; 3:83-92. PMC: 5045092. DOI: 10.2147/HP.S93413. View

Duan B, Han L, Ming S, Li J, Wang Q, Zhang D . Fuling-Guizhi Herb Pair in Coronary Heart Disease: Integrating Network Pharmacology and In Vivo Pharmacological Evaluation. Evid Based Complement Alternat Med. 2020; 2020:1489036. PMC: 7251461. DOI: 10.1155/2020/1489036. View

Huang L, Xie D, Yu Y, Liu H, Shi Y, Shi T . TCMID 2.0: a comprehensive resource for TCM. Nucleic Acids Res. 2017; 46(D1):D1117-D1120. PMC: 5753259. DOI: 10.1093/nar/gkx1028. View

Kachamakova-Trojanowska N, Podkalicka P, Bogacz T, Barwacz S, Jozkowicz A, Dulak J . HIF-1 stabilization exerts anticancer effects in breast cancer cells in vitro and in vivo. Biochem Pharmacol. 2020; 175:113922. DOI: 10.1016/j.bcp.2020.113922. View

10.

Kuo C, Cheng C, Hou P, Lin Y, Ma H, Chung Y . HIF-1-alpha links mitochondrial perturbation to the dynamic acquisition of breast cancer tumorigenicity. Oncotarget. 2016; 7(23):34052-69. PMC: 5085137. DOI: 10.18632/oncotarget.8570. View

11.

Semenza G . Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10):721-32. DOI: 10.1038/nrc1187. View

12.

Garrido-Castro A, Lin N, Polyak K . Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov. 2019; 9(2):176-198. PMC: 6387871. DOI: 10.1158/2159-8290.CD-18-1177. View

13.

Chen J, Qin Y, Sun C, Hao W, Zhang S, Wang Y . Clinical study on postoperative triple-negative breast cancer with Chinese medicine: Study protocol for an observational cohort trial. Medicine (Baltimore). 2018; 97(25):e11061. PMC: 6023942. DOI: 10.1097/MD.0000000000011061. View

14.

Park S, Choi J, Nam J . Targeting Cancer Stem Cells in Triple-Negative Breast Cancer. Cancers (Basel). 2019; 11(7). PMC: 6678244. DOI: 10.3390/cancers11070965. View

15.

Schmid P, Adams S, Rugo H, Schneeweiss A, Barrios C, Iwata H . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379(22):2108-2121. DOI: 10.1056/NEJMoa1809615. View

16.

Khosravi-Shahi P, Cabezon-Gutierrez L, Aparicio Salcedo M . State of art of advanced triple negative breast cancer. Breast J. 2019; 25(5):967-970. DOI: 10.1111/tbj.13369. View

17.

Fan C, Wu F, Zhang J, Jiang H . A Network Pharmacology Approach to Explore the Mechanisms of Shugan Jianpi Formula in Liver Fibrosis. Evid Based Complement Alternat Med. 2020; 2020:4780383. PMC: 7306883. DOI: 10.1155/2020/4780383. View

18.

Zhuang Z, Chen Q, Huang C, Wen J, Huang H, Liu Z . A Comprehensive Network Pharmacology-Based Strategy to Investigate Multiple Mechanisms of HeChan Tablet on Lung Cancer. Evid Based Complement Alternat Med. 2020; 2020:7658342. PMC: 7277035. DOI: 10.1155/2020/7658342. View

19.

Chen Y, Guan Y, Wang J, Ma F, Luo Y, Chen S . Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China. Int J Cancer. 2020; 147(12):3490-3499. DOI: 10.1002/ijc.33175. View

20.

Liu Y, Song H, Yu S, Huang K, Ma X, Zhou Y . Protein Kinase D3 promotes the cell proliferation by activating the ERK1/c-MYC axis in breast cancer. J Cell Mol Med. 2020; 24(3):2135-2144. PMC: 7011155. DOI: 10.1111/jcmm.14772. View